Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review
Open Access
- 20 December 2023
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 14 (1) , 6
Abstract
It is important to examine the psychotropic prescription practices in schizophrenia, as it can inform regarding changing treatment choices and related patient profiles. No recent reviews have evaluated the global neuropsychopharmacological prescription patterns in adults with schizophrenia. A systematic search of the literature published from 2002 to 2023 found 88 empirical papers pertinent to the utilization of psychotropic agents. Globally, there were wide inter-country and inter-regional variations in the prescription of psychotropic agents. Overall, over time there was an absolute increase in the prescription rate of second-generation antipsychotics (up to 50%), mood stabilizers (up to 15%), and antidepressants (up to 17%), with an observed absolute decrease in the rate of antipsychotic polypharmacy (up to 15%), use of high dose antipsychotic (up to 12% in Asia), clozapine (up to 9%) and antipsychotic long-acting injectables (up to 10%). Prescription patterns were mainly associated with specific socio-demographic (such as age), illness (such as illness duration), and treatment factors (such as adherence). Further work, including more evidence in adjunctive neuropsychopharmacological treatments, pharmaco-economic considerations, and examination of cohorts in prospective studies, can proffer insights into changing prescription trends relevant to different treatment settings and predictors of such trends for enhancement of clinical management in schizophrenia.Keywords
This publication has 135 references indexed in Scilit:
- Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTherapeutic Advances in Psychopharmacology, 2013
- Antipsychotic Polypharmacy in Inpatients with Schizophrenia in Asia (2001−2009)Pharmacopsychiatry, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesisBipolar Disorders, 2009
- Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national studyBMC Psychiatry, 2009
- High‐dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studiesBritish Journal of Clinical Pharmacology, 2008
- Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled TrialsSchizophrenia Bulletin, 2008
- Antipsychotic treatment patterns and hospitalizations among adults with schizophreniaSchizophrenia Research, 2008
- Outpatient Antipsychotic Treatment and Inpatient Costs of SchizophreniaSchizophrenia Bulletin, 2007